See a full list of all the cancers that the TruCheck can screen for:
Trucheck leverages a groundbreaking approach to cancer detection by targeting Circulating Tumour Cells (CTCs) and their clusters. These cells and clusters, discovered in the blood of almost all solid organ cancer patients, serve as reliable biomarkers for the presence of cancer and are virtually undetectable in healthy individuals.
This technology is backed by rigorous and extensive clinical validations involving over 40,000 participants. These validations have established the efficacy of CTCs and their clusters as hallmarks of cancer, leading to the effective implementation of the Trucheck technology.
The Trucheck test is more than just a new method—it signifies a paradigm shift in cancer screening. Deviating from traditional methods, this test neither involves radiation nor any invasive procedures. All tests are carried out in a state-of-the-art laboratory, which not only meets but also exceeds all national and international standards.
By applying the Trucheck technology, we can detect and characterise CTCs, thus offering a new and effective means of early cancer detection. Through this test, we’re taking a major stride toward revolutionising the approach to cancer screening, making it more accessible, non-invasive, and accurate.
If a potential cancer signal is identified in the form of CTCs, further diagnostic tests are recommended to confirm a cancer diagnosis. The results from TruCheck can guide doctors to the potential origin of the cancer, facilitating a focused diagnostic approach.
Please note, TruCheck is a screening test and does not diagnose cancer itself. While it offers a ground-breaking tool for early detection, additional diagnostic testing is necessary to confirm a cancer diagnosis. Furthermore, TruCheck is not a genetic risk assessment tool and does not predict future risk of developing cancer. It operates by detecting existing cancer signals, not potential genetic predispositions.
You will receive your test results about two weeks after your blood sample is taken.
There are three possible results:
– Positive for malignancy: CTCs were detected in the blood sample. The analysis suggests the likely organ of origin and malignancy type.
– Negative for malignancy: CTCs are not detected in the given sample. The chance of
having an active malignancy present in the body is low.
– Indeterminate: CTCs were detected in the given blood sample; however, type of malignancy or organ of origin could not be determined. A recollection of a blood sample is required to determine result (free of charge).
The TruCheck test is a multicancer early detection test which can detect cancer signals for 70 types of cancer from a single blood draw.
Adrenal (Neuroendocrine)
Anorectal (Squamous Cell Carcinoma)
Bile Duct (Adenocarcinoma)
Bladder (Transitional Cell Carcinoma)
Breast (Adenocarcinoma)
Buccal Mucosa (Squamous Cell Carcinoma)
Carcinosarcoma (Sarcomas)
Cervix (Squamous Cell Carcinoma)
Chondrosarcoma (Sarcomas)
Colon (Adenocarcinoma)
Colon (Gastrointestinal Stromal Tumors)
Colon (Neuroendocrine)
Cutaneous (Melanomas)
Duodenum (Adenocarcinoma)
Duodenum (Gastrointestinal Stromal Tumors)
Duodenum (Neuroendocrine)
Esophagus (Neuroendocrine)
Gallbladder (Adenocarcinoma)
Glioma
Hard Palate (Squamous Cell Carcinoma)
Ileum (Adenocarcinoma)
Ileum (Gastrointestinal Stromal Tumors)
Ileum (Neuroendocrine)
Jejunum (Adenocarcinoma)
Jejunum (Gastrointestinal Stromal Tumors)
Jejunum (Neuroendocrine)
Kidney (Renal Cell Carcinoma)
Larynx (Squamous Cell Carcinoma)
Leiomyosarcoma (Sarcomas)
Lip (Squamous Cell Carcinoma)
Liposarcoma (Sarcomas)
Liver (Adenocarcinoma)
Lung (Adenocarcinoma)
Lung (Adenosquamous Carcinoma)
Lung (Neuroendocrine)
Lung (Small Cell Lung Cancer)
Lung (Squamous Cell Carcinoma)
Mucosal (Melanomas)
Oesophagus (Adenocarcinoma)
Oesophagus (Adenosquamous Carcinoma)
Oesophagus (Squamous Cell Carcinoma)
Oral Cavity (Squamous Cell Carcinoma)
Osteosarcoma (Sarcomas)
Ovary (Adenocarcinoma)
Pancreas (Adenocarcinoma)
Pancreas (Neuroendocrine)
Paranasal Sinus (Squamous Cell Carcinoma)
Penis (Squamous Cell Carcinoma)
Peritoneal (Mesothelioma)
Pharynx (Squamous Cell Carcinoma)
Plural (Mesothelioma)
Prostate (Adenocarcinoma)
Prostate (Neuroendocrine)
Pyriform Fossa (Squamous Cell Carcinoma)
Rectum (Adenocarcinoma)
Rectum (Gastrointestinal Stromal Tumors)
Rectum (Neuroendocrine)
Renal Pelvis (Transitional Cell Carcinoma)
Retromolar Trigone (Squamous Cell Carcinoma)
Salivary Duct (Adenocarcinoma)
Skin (Squamous Cell Carcinoma)
Soft Palate (Squamous Cell Carcinoma)
Stomach (Adenocarcinoma)
Stomach (Gastrointestinal Stromal Tumors)
Thymus (Neuroendocrine)
Thyroid (Adenocarcinoma)
Tongue (Squamous Cell Carcinoma)
Tonsil (Squamous Cell Carcinoma)
Ureter (Transitional Cell Carcinoma)
Uterus (Adenocarcinoma)
Vagina (Squamous Cell Carcinoma)
Vulva (Squamous Cell Carcinoma)
The TruCheck test is suggested for use in adults with a higher risk of cancer, typically those aged 50 or above. TruCheck does not detect all types of cancers and should be considered a supplemental tool alongside routine cancer screening tests advised by your healthcare provider. The primary goal of TruCheck is to identify cancer signals and predict their origin within the body. It is not recommended for use in individuals who are pregnant, under the age of 40, or currently undergoing active cancer treatment.
Results must be analysed by a healthcare professional, taking into account the patient’s medical history, clinical signs, and symptoms. A result of “No Cancer Signal Detected” does not definitively exclude the presence of cancer. Likewise, a “Cancer Signal Detected” result necessitates further diagnostic evaluation through established medical procedures (such as imaging) to confirm the presence of cancer.
In cases where further testing does not confirm cancer, this could indicate either the absence of cancer or that the test was unable to detect it, including situations where the cancer is located in a different part of the body. Be aware that false-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) results can occur.
1. Akolkar et al. B15: Circulating tumor cells express tissue specific antigens in multiple cancers. Clin Cancer Res.2020;
26(11_Suppl). DOI: 10.1158/1557-3265.LiqBiop20-B15.
2. Akolkar et al. Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. Int. J.
Cancer:2019; 146, 3485-3494. DOI: 10.1002/ijc.32815.
3. Gaya A et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol.
2020; 129 (3) 226-238 doi: 10.1002/cncy.22366.
4. Ranade A et al. Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer
Prev Res. 2021;14:11-6 DOI:10.1158/1940-6207.CAPR-20-0322.
5. Crook T et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers
(Basel). 2022 Jul; 14(14): 3341. DOI: 10.3390/cancers14143341.
